GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Marx N, Husain M, Lehrke M, Verma S, et al. Circulation 2022;146:1882-1894.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Marx N, Husain M, Lehrke M, Verma S, et al. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation 2022;146:1882-1894.
PMID: 36508493